Evidence map›Paper›PMID 35512141›Full record

ArticleThe Journal of infectious diseases2022

Babesia duncani as a Model Organism to Study the Development, Virulence, and Drug Susceptibility of Intraerythrocytic Parasites In Vitro and In Vivo.

Anasuya C Pal, Isaline Renard, Pallavi Singh, Pratap Vydyam, Joy E Chiu, Sovitj Pou, Rolf W Winter, Rozalia Dodean, Lisa Frueh, Aaron C Nilsen and 3 more

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Revisiting 2-Substituted-4(1Journal of medicinal chemistry · 2026
    Article
  5. Evaluating acridones as novel therapeutics for human babesiosis.Antimicrobial agents and chemotherapy · 2026
    Article
  6. Article
  7. A propidium iodide-basedAntimicrobial agents and chemotherapy · 2025
    Article
  8. Article
  9. Article
  10. A set of diagnostic tests for detection of active Babesia duncani infection.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024
    Article
  11. Antimicrobial agents and chemotherapy · 2024
    Article
  12. Article
  13. Review
  14. Transfection ofBio-protocol · 2024
    Article
  15. Synthesis of Deuterated Endochin-Like Quinolones.Journal of labelled compounds & radiopharmaceuticals · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Anasuya C PalSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Isaline RenardSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0003-4121-143X
Pallavi SinghSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Pratap VydyamSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Joy E ChiuSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
Sovitj PouVeterans Affairs Portland Health Care System, Portland, Oregon, USA.
Rolf W WinterVeterans Affairs Portland Health Care System, Portland, Oregon, USA.
Rozalia DodeanVeterans Affairs Portland Health Care System, Portland, Oregon, USA.
Lisa FruehVeterans Affairs Portland Health Care System, Portland, Oregon, USA.
Aaron C NilsenVeterans Affairs Portland Health Care System, Portland, Oregon, USA.
Michael K RiscoeVeterans Affairs Portland Health Care System, Portland, Oregon, USA.
J Stone DoggettVeterans Affairs Portland Health Care System, Portland, Oregon, USA.ORCID 0000-0002-6098-1520
Choukri Ben MamounSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.

Funding

Optimizing ELQs for Treatment and Prevention of MalariaR01AI100569 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Michael Kevin RISCOE · 2014 to 2026
$8.0M
Fosinopril analogs for the treatment of human babesiosisR01AI153100 · NIAID · YALE UNIVERSITY · PI BEN MAMOUN, CHOUKRI · 2021 to 2025
$3.6M
Hit-to-Lead Development of the Kalihinol Scaffold for Malaria TreatmentR01AI138139 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BEN MAMOUN, CHOUKRI, LE ROCH, KARINE GAELLE · 2018 to 2022
$3.6M
Development of a Sustained Release Injectable Formulation for Long-Term Delivery of ELQsR01AI141412 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI RISCOE, MICHAEL KEVIN · 2019 to 2022
$3.2M
Development of endochin-like quinolones for babesiosis therapyR01AI123321 · NIAID · YALE UNIVERSITY · PI BEN MAMOUN, CHOUKRI · 2017 to 2020
$2.7M
Antigen Discovery and Vaccine Development for Human Babesia ParasitesR01AI152220 · NIAID · YALE UNIVERSITY · PI BEN MAMOUN, CHOUKRI · 2020 to 2024
$2.1M
An antigen-detection assay to diagnose Babesia microti infectionR44AI136118 · NIAID · L2 DIAGNOSTICS, LLC · PI LEDIZET, MICHEL · 2020 to 2022
$2.1M
An antigen-detection assay to diagnose Babesia microti infectionR43AI136118 · NIAID · L2 DIAGNOSTICS, LLC · PI LEDIZET, MICHEL · 2018 to 2018
$300k
Novel Therapeutic Strategies for ELQ-422, a preclinical Toxoplasmosis Drug CandidateI01BX004522 · VA · PORTLAND VA MEDICAL CENTER · PI Joseph Stone Doggett · 2019 to 2026
–
BLRD VA I01 BX003312BLRD VA I01 BX004522NIAID NIH HHS R01 AI100569NIAID NIH HHS R01 AI123321NIAID NIH HHS R01 AI138139NIAID NIH HHS R01 AI141412NIAID NIH HHS R01 AI152220NIAID NIH HHS R01 AI153100NIAID NIH HHS R43 AI136118NIAID NIH HHS R44 AI136118NIH HHS R01AI123321Veterans Affairs Biomedical Laboratory Research and Development
6 · The paper itself

Abstract

Human babesiosis is a malaria-like illness caused by tick-borne intraerythrocytic Babesia parasites of the Apicomplexa phylum. Whereas several species of Babesia can cause severe disease in humans, the ability to propagate Babesia duncani both in vitro in human erythrocytes and in mice makes it a unique pathogen to study Babesia biology and pathogenesis. Here we report an optimized B. duncani in culture-in mouse (ICIM) model that combines continuous in vitro culture of the parasite with a precise model of lethal infection in mice. We demonstrate that B. duncani-infected erythrocytes as well as free merozoites can cause lethal infection in C3H/HeJ mice. Highly reproducible parasitemia and survival outcomes could be established using specific parasite loads in different mouse genetic backgrounds. Using the ICIM model, we discovered 2 new endochin-like quinolone prodrugs (ELQ-331 and ELQ-468) that alone or in combination with atovaquone are highly efficacious against B. duncani and Babesia microti.

Indexed as

BabesiaParasitesProdrugsQuinolonesTicksAnimalsAtovaquoneHumansMiceMice, Inbred C3HVirulenceAtovaquoneProdrugsQuinolonesApicomplexaBabesia duncanibabesiosiserythrocytesparasite

Identifiers

PMID35512141
PMCPMC10233494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.